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Introduction

60
Despite major advances in pharmacological treatment, hypertension is an increasingly common health problem worldwide. 1 Blood pressure (BP) control in patients on antihypertensive medication has been evaluated as unsatisfactory in the United
States, Canada, and other European countries. 2 In Japan, it was estimated that, in the 65 year 2008, 39 million people had hypertension (i.e., nearly 38% of the adult population), almost half of them were untreated, 3 and the control of hypertension iñ 50% of those on antihypertensive medication was not satisfactory. 4 Recent meta-analyses have demonstrated that team-based care involving a pharmacist can improve hypertension control. 5 Most physician-pharmacist 70 comanagement programs are designed to provide a clinically satisfactory control of BP in patients through the addition/substitution of suitable medications, titration of dosages, and/or enhancement of adherence to therapy. [6] [7] [8] Although lifestyle modifications are known to enhance the antihypertensive effects of medications and help to reduce the required dosage of drugs, 9 the programs described did not focus on 75 this issue. Pharmacist-based medication counseling, including counseling regarding lifestyle modification, could contribute to reductions in both the number and dosage of antihypertensive agents; however, this needs to be confirmed by a thorough analysis.
We conducted a randomized-controlled trial to test the a priori hypothesis that physician-pharmacist cooperation can reduce antihypertensive medication use and 
Physician-pharmacist program of cooperation
After a 1-month run-in period, the participants were randomized into the intervention or control group in a 1:1 ratio, using a computer-generated random number sequence 115 provided by a statistician who had no contact with the participants. The randomization assignment details were revealed to participants as well as study personnel only after the completion of baseline data collection. The study team comprised five physicians and a pharmacist who had been trained to measure office BP in accordance with the Japanese Society of Hypertension Guidelines for the Management of Hypertension
120
(JSH 2004), 10 and all the personnel adhered to the study protocol. The pharmacist had worked in the clinic for >10 years and had participated in research activities involving provision of health services at Tsukuba University.
In the first 20 min of the first session, printed educational leaflets about treatment of hypertension were distributed to the participants. The intervention group 125 received subsequent 15-min sessions of monthly individual counseling for 6 months ( 10 The physicians discussed the treatment plan with the pharmacist over the telephone, or face-to-face if necessary, during the examination of the patient.
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The follow-up protocol for patients of the control group was similar to that for the intervention group, but the pharmacist's monthly sessions and reports to the galley, #AJH-tobari, Page 10 physician were omitted ( were given the same counseling sessions in the 6 months after the end of the intervention period. for both the intervention and control groups based on a standardized regimen ( Figure   2 ). For the purpose of attaining better control of BP and/or avoid side effects, changing medications and/or the timings of medication administration were carried out throughout the trial as required.
Outcomes
1) Distribution of antihypertensive medications
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All recommendations regarding the prescription medications made by the 175 pharmacist were approved by the physicians.
2) BP measurements
In accordance with the guidelines of JSH2004, both office and home BPs were each of the two indicated time periods, the first reading was used for the analysis.
These procedures were followed in every instance, and have been described in detail previously. 15 All the patients were also advised to record in writing the BP readings at the time of measurement of BP using the automated device. Measurements behaviors. This scoring system has been validated previously. 11, 16 The correlation between sodium reduction score and sodium excretion has also been determined previously. Age-and sex-adjusted mean 24-h sodium excretion values across quintiles of the baseline sodium reduction score (n = 1,674) were 203, 195, 183, 180, 168 galley, #AJH-tobari, Page 13 mmol/day (P for trend <0.0001). 16 Data relating to 24-h sodium excretion values are 220 not reported for this study because of the limited sample size (84/132 patients, 64%).
All laboratory assays, blinded as to identification of the patient, were analyzed at Kotobiken Medical Laboratories (Tsukuba, Japan), using standard methods.
Statistical analysis
225
Our planned sample size of ≥63 patients per group had to be randomized to detect 7 or Analyses were performed according to the intention-to-treat principle.
Differences in baseline characteristics between the intervention and control groups 240 were tested for significance using the independent t, the Wilcoxon rank sum, or χ 2 -tests. Fisher's exact test was used to assess differences in adherence to medication.
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We compared 6-month changes in BP levels, and clinical and lifestyle variables between the two groups using the analysis of covariance for continuous outcomes and multiple logistic regression model for binary outcomes. We controlled for potential 245 baseline confounding by BMI (kg/m 2 ), which was the only baseline characteristic having a P value <0.10 for between-group comparisons, home morning SBP ≥135
and/or DBP ≥85 mm Hg (yes or no), and antihypertensive medication use (yes or no).
Two-tailed P values of <0.05 were considered statistically significant. In order to minimize the hypotheses tested, we considered home morning BP and reductions in 250 antihypertensive medications as the primary outcomes. All analyses were performed using SAS software version 9.1 (SAS Institute, Cary, NC).
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Results
Study Flow and Baseline Characteristics
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Of the 236 eligible patients who met the entry criteria, 132 (56%) agreed to be enrolled in the study (Figure 1 ). The proportion of those of age >60 years was somewhat higher among those who consented to enroll than in the general pool of eligible patients, probably more of the younger, working-age patients could not spare the time required for the study. Of the 132 patients enrolled (66 in each group), 64 260 from each group attended the 6-month follow-up; the follow-up rate in each group was therefore 97%. Four patients did not complete the study: one was lost to follow-up; two dropped-out, and one underwent surgery during the follow-up phase.
Throughout the trial none of the patients developed cardiovascular events that 
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At 6 months, the mean office DBP diminished relative to the baseline in the intervention group (SBP by 2.4 mm Hg, P =0.14, and DBP by 2.3 mm Hg, P = 0.02) as well as in the control group (SBP by 0.9 mm Hg, P = 0.45, and DBP by 3.1 mm Hg, P = 0.002, respectively), but the differences between the two groups in this regard 300 were not significant ( Table 3 ). The mean home morning values of SBP and DBP in the intervention group also decreased relative to the baseline by 2.9 (P =0.02) and 3.3 mm Hg (P <0.0001), respectively. The mean decrease in home morning SBP in the intervention group was not significantly greater than in the control group. However, the DBP decline was significantly greater in the intervention than control groups, 305 which showed a mean decrease of 2.8 mm Hg (confidence interval: -5.5 to -0.1; P = 0.04). The proportion of patients in whom the control of home morning BP was achieved was 53% in the intervention group and 47% in the control group, and no significant difference was noted in this regard between the groups (P = 0.40). At the 6-month follow-up, home evening BP levels 310 were similar to the baseline in the intervention group whereas they had increased in the control group. Similar results were noted after excluding from the analysis data relating to patients who did not receive antihypertensive medications.
Changes in cardiovascular risk factors and lifestyle modification
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At 6 months, the decrease in BMI was significantly greater in the intervention group than in the control group (Table 4) . Larger proportions of patients in the intervention group improved their sodium reduction scores and achieved smoking cessation as compared to the control group (P = 0.002 and P = 0.04, respectively, for the two the percentages of such patients were not significantly different in the two groups (P = 0.23, P = 0.09, respectively).
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Discussion
The physician-pharmacist cooperation in this study, aimed at promoting appropriate 325 changes in antihypertensive medications and dosing regimens and also in the lifestyles of patients with mild to moderate hypertension, was shown to improve the control of home morning DBP and reduce the use of antihypertensive medication. It also resulted in a decrease in BMI, sodium intake, and the use of tobacco. Previous studies have targeted patients with hypertension to improve adherence to medication regimens 330 and to increase the use/dosage of antihypertensive drugs as needed. The novelty of the present study is that it was designed to bring about reductions in BP levels through lifestyle modification and medication changes. Specifically, the approach we adopted was able to achieve BP control in patients even while reducing or discontinuing the use of antihypertensive agents. In this study, although the magnitude of reduction in home morning BP was relatively small, same as the expected reduction level improved by lifestyle modification, 17, 18 it may be of value, given that 3-5 mm Hg of reduction in BP is reported to reduce potential adverse cardiac events and stroke. 23 Moreover, a recent galley, #AJH-tobari, Page 20 study showed that lifestyle modification improved the outcome of medical treatment;
it was shown in patients with hypertension that, over a 10-year period, a reduction in intake of salt by 1 g/day achieved BP control that was equivalent to and far more cost-effective than the use of antihypertensive medications. 24 Consequently, it has been recommended that more emphasis be placed on lifestyle modification to control 
